EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by Janssen-Cilag International N.V. EMA’s human medicines […]
TrialSite predicted months ago that the vaccine, sponsored by the world’s largest pharmaceutical company by revenue–Johnson & Johnson, could become […]
St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center (UTHSC) now offer a testing site for […]
Johannesburg’s Helen Joseph Hospital was selected by Janssen Pharmaceutical Companies of Johnson & Johnson as a trial site organization for […]
Janssen Research & Development, LLC (Janssen), a part of Johnson & Johnson, inked a partnership with a patient-centered health intelligence […]
The government of the United Kingdom reported in a press release that it has secured early access to 90 million […]
Janssen Pharmaceuticals announced the phase 3 LOTUS study, evaluating Stelara (ustekinumab) in patients with Systemic Lupus Erythematosus (SLE) will be […]
Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the […]
Beth Israel Deaconess Medical Center (BIDMC) inked a collaborative deal with Johnson & Johnson’s Janssen Pharmaceutical Co to develop a […]
Janssen announced the U.S. Food and Drug Administration (FDA) granted JNJ-6372 Breakthrough Therapy Designation for metastatic non-small cell lung cancer […]
